It showed a safety profile and promising antitumor activity in patients with HER2-positive advanced gastric or gastroesophageal junction cancer, which led to a phase II clinical trial (NCT05985707) in HER2-positive CRC patients [70]. Here, ERBB2 is linked to colorectal carcinoma.